

## PEDIATRIC

# PHARMACOLOGY

Therapeutic Principles in Practice



# PEDIATRIC PHARMACOLOGY

### **Therapeutic Principles in Practice**

#### SUMNER J. YAFFE, M.D.

Director
Center for Research for Mothers and Children
National Institute of Child Health and Human Development
Bethesda, Maryland

#### JACOB V. ARANDA, M.D., Ph.D., F.R.C.P.(C)

Professor of Pediatrics and of Pharmacology and Therapeutics McGill University, School of Medicine; Director Developmental Pharmacology and Perinatal Research Unit Montreal Children's Hospital, Department of Pediatrics Montreal, Quebec

#### W.B. SAUNDERS COMPANY

Harcourt Brace Jovanovich, Inc.

Philadelphia, London, Toronto, Montreal, Sydney, Tokyo

W. B. SAUNDERS COMPANY Harcourt Brace Jovanovich, Inc.

The Curtis Center Independence Square West Philadelphia, Pennsylvania 19106

#### Library of Congress Cataloging-in-Publication Data

Pediatric pharmacology: therapeutic principles in practice / [edited by] Sumner J. Yaffe, Jacob V. Aranda. — 2nd ed.

cm.

Includes bibliographical references and index. ISBN 0-7216-2971-7

 $1. \ \ Pediatric\ pharmacology. \ \ I. \ \ Yaffe, Sumner\ J., \quad II. \ \ Aranda, Jacob\ V.$ [DNLM: 1. Drug Therapy—in infancy & childhood. WS 366 P369] RJ560.P4 1992

615.5'8-083-dc20

DNLM/DLC

for Library of Congress

91-37728

CIP

Editor: Judith Fletcher

#### PEDIATRIC PHARMACOLOGY

Therapeutic Principles in Practice

ISBN 0-7216-2971-7

Copyright © 1992, 1980 by W. B. Saunders Company.

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

Printed in Mexico.

Last digit is the print number:

987654321

Dedicated to
Anita and Ian
and
Betty, Kenneth, and Christopher
for their unswerving love and support

## **CONTRIBUTORS**

#### GAD ALPAN, M.D.

Assistant Professor, Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, New York

Drug Treatment of Neonatal Apnea

#### MONIQUE ANDRE, M.D.

Pediatric Neurologist, Department of Neonatology, Maternity Hospital, Nancy, France Anticonvulsants in the Newborn Infant

#### JACOB V. ARANDA, M.D., Ph.D., F.R.C.P.(C.)

Professor of Pediatrics and of Pharmacology and Therapeutics, McGill University Faculty of Medicine and Attending Neonatologist and Director, Developmental Pharmacology and Perinatal Research, Montreal Children's Hospital, Montreal, Canada

Introduction and Historical Perspectives; Drug Treatment of Neonatal Apnea

#### B. M. ASSAEL, M.D.

Associate Professor of Pediatrics, Clinica Pediatrica, Universita di Milano, Milan, Italy Aminoglycoside Antibiotics

#### ANNABELLE AZANCOT-BENISTY, M.D., Ph.D.

Fetal Cardiology Department, Faculté Lariboisuie, St. Louis, Hôpital Robert Debré. Head, Physiology Department, Cardiovascular Physiology, Fetal Cardiology Unit, Hôpital Robert Debré, Paris, France

Fetal Pharmacology and Therapy: Supraventricular Arrhythmias as an Example

#### CHESTON M. BERLIN, Jr., M.D.

University Professor of Pediatrics, Professor of Pharmacology and Chief, Division of General Pediatrics, Milton S. Hershey Medical Center, The Pennsylvania State University, Hershey, Pennsylvania

The Excretion of Drugs and Chemicals in Human Milk

#### C. WARREN BIERMAN, M.D.

Clinical Professor of Pediatrics, University of Washington. Director, Division of Allergy, Children's Hospital and Medical Center, Seattle, Washington

Antihistamines

#### PIERRE BLANCHARD, M.D.

Associate Professor of Pediatrics, Université de Sherbrooke. Head, Division of Neonatology and Assistant Director of Pediatrics, Centre Hospitalier, Université de Sherbrooke, Sherbrooke, Quebec, Canada

Drug Treatment of Neonatal Apnea

#### JEFFREY L. BLUMER, Ph.D., M.D.

Carrie R. Kohn Professor of Pediatric Critical Care Medicine, Department of Pediatrics, School of Medicine, Case Western University. Chief, Division of Pediatric Pharmacology and Critical Care, Rainbow Babies' and Children's Hospital, Cleveland, Ohio

Drugs Used to Modulate Gastrointestinal Function; Principles of Neonatal Pharmacology

#### LARS O. BOREUS, M.D.

Professor and Chairman, Department of Clinical Pharmacology, Karolinska Hospital, Stockholm, Sweden

Therapeutic Drug Monitoring

#### J. CHRISTOPHER CAREY, M.D.

Associate Professor, University of Oklahoma. Chief, Benign Gynecology, Oklahoma Teaching Hospital, Oklahoma City, Oklahoma

Drugs Used in Labor and Delivery

#### CHARLOTTE S. CATZ, M.D.

Chief, Pregnancy and Perinatology Branch, Center for Research for Mothers and Children, National Institute of Child Health and Human Development, Bethesda, Maryland

Drugs Used in Labor and Delivery

#### GEORGE P. CHROUSOS, M.D.

Chief, Pediatric Endocrinology Section, Developmental Endocrinology Branch, National Institute of Child Health and Human Development, Bethesda, Maryland

Glucocorticoids

#### CAROL CISTOLA, M.D.

Department of Obstetrics and Gynecology, University of Arkansas for Medical Science, Little Rock, Arkansas

Physiological Adaptations to Pregnancy: Impact on Pharmacokinetics

#### SANFORD N. COHEN, A.B., M.D.

Professor of Pediatrics, Department of Pediatrics, Wayne State University School of Medicine. Distinguished Attending Physician, Children's Hospital of Michigan, Detroit, Michigan Ethics of Drug Research in Children

#### ELEANOR COLLE, M.D.

Professor of Pediatrics, McGill University. Physician, Montreal Children's Hospital, Montreal, Quebec, Canada

Insulin and Diabetes Mellitus

#### MICHELE DANISH, Pharm.D.

Assistant Professor, Department of Pharmaceutics, University of Rhode Island College of Pharmacy, Kingston, Rhode Island

Clinical Pharmacokinetics

#### WILLIAM E. EVANS, Pharm.D.

First Tennessee Professor of Clinical Pharmacy, College of Pharmacy, and Professor of Pediatrics,

College of Medicine, University of Tennessee. Chairman, Pharmaceutical Division and Member, Saint Jude Children's Research Hospital, Memphis, Tennessee

Antineoplastic Agents

#### FABIAN EYAL, M.D.

Director, Division of Neonatology, Francis Scott Key Medical Center and Johns Hopkins University School of Medicine, Baltimore, Maryland

Drug Treatment of Neonatal Apnea

#### DELBERT A. FISHER, M.D.

Emeritus Professor of Pediatrics and Medicine, University of California School of Medicine, Los Angeles. Senior Scientist, Research and Education Institute, Harbor-UCLA, Los Angeles. Medical Center, Torrance, California

Thyroid Hormones

#### F. C. FRASER, M.D., Ph.D., F.R.S.

Professor Emeritus, Centre for Human Genetics, McGill University. Medical Genetics, The Montreal Children's Hospital, Montreal, Quebec, Canada

**Teratology** 

#### PETER GAL, Pharm.D., F.C.C.P.

Clinical Professor, School of Pharmacy, University of North Carolina at Chapel Hill. Clinical Associate Professor, Department of Family Medicine, University of North Carolina School of Medicine. Director, Pharmacy Education and Research, Greensboro Area Health Education Center. Codirector, Clinical Pharmacology Research and Development Laboratory, Moses H. Cone Memorial Hospital, Greensboro, North Carolina

Therapeutic Drug Monitoring: Theoretical and Practical Issues

#### R. GHADIALLY, M.B., Ch.B., F.R.C.P.(C.)

Division of Dermatology, Sunnybrook Medical Centre, Toronto, Ontario, Canada Topical Therapy and Percutaneous Absorption

#### JAMIE GILMAN, Pharm.D.

Clinical Associate Professor, School of Pharmacy, University of Florida, Gainesville. College of Pharmacy, Southeastern University of Health Sciences. Director, Section of Neuropharmacology, Comprehensive Epilepsy Center and Pharmacokinetics Laboratory, Miami Children's Hospital, Miami, Florida

Therapeutic Drug Monitoring: Theoretical and Practical Issues

#### RAFAEL GORODISCHER, M.D.

Professor and Chair, Department of Pediatrics, Clinical Pharmacology Unit, Soroka Medical Center, Ben-Gurion University of the Negev, Beer-Sheba, Israel

Cardiac Drugs; Digoxin

#### ERIC J. GREENGLASS, B.Sc., M.Sc., M.D., F.R.C.P.(C.), F.A.A.P.

Assistant Professor of Pediatrics and Attending Neonatologist, Neonatal-Perinatal Medicine, Loyola University, Chicago, Illinois

Neonatal Pharmacology: Practical Applications; Adverse Effects of Environmental Chemicals and Drugs of Abuse on the Developing Human; The Adverse Effects of Cocaine on the Developing Human

#### BARBARA F. HALES, Ph.D.

Associate Professor, Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada

Teratology: Biochemical Mechanisms

#### KAREN HEIN, M.D.

Professor of Pediatrics, Albert Einstein College of Medicine. Director, Adolescent AIDS Program, Montefiore Medical Center, Bronx, New York

Drug Therapeutics in the Adolescent

#### MALCOLM HILL, Pharm.D.

Assistant Professor of Pediatrics and Pharmacy, University of Colorado Health Sciences Center. Clinical Research Pharmacist, Clinical Pharmacology Division, National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado

Advances in the Pharmacologic Management of Asthma

#### SUSAN L. HOGUE, Ph.D.

Fellow, Pediatric Pharmacotherapy, Department of Clinical Pharmacology, Center for Pediatric Pharmacokinetics and Therapeutics, The University of Tennessee, Memphis, Tennessee Pharmacokinetically Based Drug Interactions

#### SHEILA JACOBSON, M.D.

Fellow in Clinical Pharmacology, University of Toronto. Fellow in Clinical Pharmacology, Hospital for Sick Children, Toronto, Ontario, Canada

Drug Administration in the Newborn Infant

#### EVELYNE JACQZ-AIGRAIN, M.D., Ph.D.

Pharmacology Clinic, Hôpital Robert Debré, Paris, France

Fetal Pharmacology and Therapy: Supraventricular Arrhythmias as an Example

#### KEITH JOHNSON, M.D.

Director, Drug Information Center, The U.S. Pharmacopeial Convention, Inc., Rockville, Maryland

Appendix I: Formulary

#### BERNARD S. KAPLAN, M.B., B.Ch.

Professor of Pediatrics and Medicine, University of Pennsylvania. Director, Division of Nephrology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Therapeutic Agents and the Kidney: Pharmacokinetics and Complications; Diuretics

#### SELNA L. KAPLAN, M.D., Ph.D.

Professor of Pediatrics, University of California. Attending Pediatrician, Moffit-Long Hospital, San Francisco, California

Growth Hormone

#### RALPH E. KAUFFMAN, M.D.

Professor of Pediatrics and Pharmacology, Wayne State University School of Medicine. Director, Division of Clinical Pharmacology, Vice Chairman for Clinical Affairs, Children's Hospital of Michigan, Detroit, Michigan

Drug Therapeutics in the Infant and Child

#### GIDEON KOREN, M.D., A.B.M.T., F.R.C.P.(C.)

Associate Professor, Pediatrics and Pharmacology. Director, The Motherisk Program, Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Ontario, Canada Drug Administration in the Newborn Infant; Cardiac Drugs; Digoxin

#### MARKUS J. P. KRUESI, M.D.

Child Psychology Branch, National Institute of Mental Health, Bethesda, Maryland Psychoactive Agents

#### MARC H. LEBEL, M.D., F.R.C.P.(C.)

Assistant Professor, Department of Pediatrics, University of Montreal. Attending Physician, Hôpital Sainte-Justine, Montreal, Quebec, Canada

Antifungal Agents for Systemic Mycotic Infections

#### PIERRE LEBEL, M.D., F.R.C.P.(C.)

Assistant Professor, Department of Microbiology, University of Montreal, Director of Bacteriology, Department of Microbiology, Hôpital Sainte-Justine, Montreal, Quebec, Canada Antifungal Agents for Systemic Mycotic Infections

#### CHARIS LIAPI, Ph.D.

Assistant Professor, Department of Pharmacology, Athens University Medical School, Athens, Greece

Glucocorticoids

#### JAMES G. LINAKIS, Ph.D., M.D.

Assistant Professor of Pediatrics, Brown University. Attending Physician, Departments of Emergency Medicine and Pediatrics, Rhode Island Hospital. Associate Medical Director, Rhode Island Poison Center, Providence, Rhode Island Antipyretics

#### IRIS F. LITT, M.D.

Professor of Pediatrics, Division of Adolescent Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California

Compliance with Pediatric Medication Regimens

#### JOSE MARIA LOPES, M.D., Ph.D.

Head of Neonatology, Fernandes Figueira Institute, Rio de Janeiro, Brazil Drug Treatment of Neonatal Apnea

#### FREDERICK H. LOVEJOY, Jr., M.D.

Chief of Patient Services, Department of Medicine, Children's Hospital. Professor of Pediatrics, Harvard School of Medicine Department of Medicine. Associate Physician-in-Chief, Children's Hospital, Boston, Massachusetts

Antipyretics

#### ANTOINE MALEK, Ph.D.

Women's Hospital, University of Berne, Berne, Switzerland Physiological Adaptations to Pregnancy: Impact on Pharmacokinetics

#### INGRID MATHESON, M.Sci.Pharm., Ph.D.

Associate Professor, Department of Pharmacotherapeutics, Faculty of Medicine, University of Oslo, Oslo, Norway

Drug Utilization in Non-Hospitalized Newborns, Infants, and Children

#### DONALD R. MATTISON, B.A., M.S., M.D.

Dean, Graduate School of Public Health, Professor of Environmental and Occupational Health and Obstetrics and Gynecology, University of Pittsburgh, Pittsburgh, Pennsylvania

Physiological Adaptations to Pregnancy: Impact on Pharmacokinetics

#### ELAINE L. MILLS, M.D., F.A.A.P.

Associate Professor, Departments of Pediatrics and Microbiology-Immunology, McGill University. Director of Infectious Diseases, Montreal Children's Hospital, Montreal, Quebec, Canada Antifungal Agents for Systemic Mycotic Infections

#### LAWRENCE S. MILNER, M.B., B.Ch.

Assistant Professor, University of Nebraska Medical Center. Nephrologist, Division of Nephrology, University of Nebraska Medical Center, Omaha, Nebraska

Therapeutic Agents and the Kidney: Pharmacokinetics and Complications

#### TAKASHI MIMAKI, M.D.

Assistant Professor, Department of Pediatrics, Osaka Medical College, Takatsuki City, Osaka, Japan Anticonvulsants

#### ALLEN A. MITCHELL, M.D.

Research Professor of Public Health (Epidemiology), School of Public Health, Boston University School of Medicine. Lecturer on Pediatrics, Harvard Medical School. Associate Director and Associate in Medicine (Clinical Pharmacology), Children's Hospital, Boston, Massachusetts Adverse Drug Effects and Drug Epidemiology

#### MOHAMMED AL-MUGEIREN, M.D., F.R.C.P.(C.)

King Khalid University. Consultant Pediatric Nephrologist, King Khalid University Hospital, Riyadh, Saudi Arabia

Therapeutic Agents and the Kidney: Pharmacokinetics and Complications

#### JANAK A. PATEL, M.D.

Assistant Professor, Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas

Antiviral Chemotherapy: The Penicillins

#### L. OGRA PEARAY, M.D.

Professor and Chairman, Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas

Antiviral Chemotherapy

#### ROBERT G. PETERSON, M.D., Ph.D.

Professor of Pediatrics and Pharmacology and Chairman, Department of Pediatrics, University of Ottawa. Chief, Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada

Management of Poisoning; Appendix II: SI Units

#### WILLIAM P. PETROS, Pharm.D.

Clinical Associate, Department of Medicine, Duke University. Coordinator, Gale Gould Center Drug Pharmacology Lab, Bone Marrow Transplant Program, Duke University Medical Center, Durham, North Carolina

Antineoplastic Agents

#### STEPHANIE J. PHELPS, Ph.D.

Associate Professor, Department of Clinical Pharmacology, Center for Pediatric Pharmacokinetics and Therapeutics, The University of Tennessee, Memphis, Tennessee

Pharmacokinetically Based Drug Interactions

#### RONALD L. POLAND, M.D.

Professor and Chairman, Department of Pediatrics, The Milton S. Hershey Medical Center, The Pennsylvania State University, Hershey, Pennsylvania

Ethics of Drug Research in Children

#### ANDERS RANE, M.D., Ph.D.

Professor and Chairman, Section of Clinical Pharmacology, Academic Hospital. Director, Department of Drugs, National Board of Health and Welfare, Uppsala, Sweden

Drug Disposition and Action in Infants and Children

#### JUDITH L. RAPOPORT, M.D.

Chief, Child Psychiatry Branch, National Institute of Mental Health, Bethesda, Maryland *Psychoactive Agents* 

#### MICHAEL D. REED, Pharm.D., F.C.C.P., F.C.P.

Associate Professor of Pediatrics, Department of Pediatrics, School of Medicine, Case Western Reserve University. Director, Pediatric Clinical Pharmacology and Toxicology, Rainbow Babies' and Children's Hospital, Cleveland, Ohio

Drugs Used to Modulate Gastrointestinal Function; Principles of Neonatal Pharmacology

#### FRANZ W. ROSA, M.D., M.P.H.

Epidemiologist, Office of Epidemiology and Biostatistics, Food and Drug Administration, Rockville, Maryland

Epidemiology of Drugs in Pregnancy

#### F. RUSCONI, M.D.

Clinica Pediatrica, Universita di Milano, Milan, Italy Aminoglycoside Antibiotics

#### BERNARD P. SCHACHTEL, M.D.

Adjunct Professor of Epidemiology and Biostatistics, Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada Analgesic Agents

#### ALICIA SCHIFFRIN, M.D.

Associate Professor of Pediatrics, McGill University. Academic Staff, Montreal Children's Hospital, Montreal, Quebec, Canada

Insulin and Diabetes Mellitus

#### BERNARD H. SHAPIRO, Ph.D.

Head and Professor of Biochemistry, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania

Delayed Teratogenic Expression

#### NEIL H. SHEAR, M.D., F.R.C.P.(C.)

Head, Clinical Pharmacology Staff, Division of Dermatology, Sunnybrook Medical Centre, Toronto, Ontario, Canada

Topical Therapy and Percutaneous Absorption

#### JAYANT P. SHENAI, M.D.

Associate Professor of Pediatrics, Vanderbilt University School of Medicine. Attending Neonatologist and Director, Newborn Regionalization Program, Vanderbilt University Medical Center, Nashville, Tennessee

Vitamin A Supplementation in the Very Low Birth Weight Infant

#### JOSEPH R. SHERBOTIE, M.D.

Assistant Professor of Pediatrics, University of Pennsylvania School of Medicine. Attending Nephrologist, Division of Nephrology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania Diuretics

#### ALAN R. SINAIKO, M.D.

Professor, Departments of Pediatrics and Pharmacology, Division of Nephrology, University of Minnesota Medical School. University of Minnesota Hospital and Clinics, Minnesota Antihypertensive Agents

#### ARNOLD L. SMITH, M.D.

Professor of Pediatrics, Adjunct Professor of Microbiology, University of Washington. Head, Division of Infectious Disease, Children's Hospital and Medical Center, Seattle, Washington Chloramphenicol

#### WAYNE R. SNODGRASS, M.D., Ph.D.

Professor of Pediatrics and Pharmacology-Toxicology, University of Texas Medical Branch. Head, Clinical Pharmacology-Toxicology Unit, University of Texas Medical Branch, Galveston, Texas *The Penicillins* 

#### HARRIS R. STUTMAN, M.D.

Assistant Professor, Department of Pediatrics, University of California, Irvine. Director, Pediatric Infectious Diseases, Memorial Miller Children's Hospital, Long Beach, California Cephalosporins

#### JAMES L. SUTPHEN, M.D., Ph.D.

Associate Professor of Pediatrics, Department of Pediatrics, School of Medicine, University of Virginia. Chief, Division of Pediatric Gastroenterology, University of Virginia Health Sciences Center, Charlottesville, Virginia

Drugs Used to Modulate Gastrointestinal Function

#### YASUHIRO SUZUKI, M.D.

Faculty Staff, Department of Pediatrics, Osaka University Medical School, Osaka City, Osaka, Japan Anticonvulsants

#### STANLEY J. SZEFLER, M.D.

Professor of Pharmacology and Pediatrics, University of Colorado Health Science Center. Director of Clinical Pharmacology, National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado

Advances in the Pharmacologic Management of Asthma

#### PAUL VERT, M.D.

Professor of Pediatrics, Université de Nancy, Faculté de Medecine. Head, Department of Neonatology, Maternity Hospital, Nancy, France

Anticonvulsants in the Newborn Infant

#### ELLIOT S. VESELL, M.D.

Chairman, Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania

**Pharmacogenetics** 

#### PHILIP D. WALSON, M.D.

Professor of Pediatrics, Pharmacology, Pharmacy and Allied Health Services, The Ohio State University. Division Head, Clinical Pharmacology/Toxicology, Columbus Children's Hospital, Columbus, Ohio

Anticonvulsants

#### SUMNER J. YAFFE, M.D.

Director, Center for Research for Mothers and Children, National Institute of Child Health and Human Development, Bethesda, Maryland

Introduction and Historical Perspectives

# FOREWORD to the Second Edition

In ancient times children were regarded as small adults and received little consideration. When the modern era of medical treatment began with the introduction of penicillin in the late 1940s, no thought was given to the correct dosage for infants and children other than to guess and give less. It took a series of therapeutic disasters (1950–1970) to convince people of the uniqueness of infants and children. For years finding the correct dose of a medication for an infant or child was a confusing process. No authoritative source existed until 1979.

This textbook of pediatric pharmacology was "born" in 1979. The second edition has grown and matured dramatically, reflecting the rapid advances in this subject during the past eleven years.

Seventy of the top international authorities in the field have been chosen to write on sixty subjects of major practical interest to all practicing pediatricians. This is clearly the most authoritative text in the field.

This textbook will often be consulted. It contains all of the information you need to know about a drug and how to use it intelligently. It is well organized, clear, comprehensive, and succinct. The editors have done an excellent job in covering this important field and establishing this book as the classic in its field.

JEROLD F. LUCEY, M.D.

Professor of Pediatrics
Editor of Pediatrics
UVM College of Medicine
Chief, Newborn Services
Medical Center Hospital of Vermont

# FOREWORD from the First Edition

During the past decade, pediatric pharmacology has progressed from a subcomponent of adult therapeutics to a well-defined and recognized medical specialty. Clinical misfortunes, such as the chloramphenicol–gray syndrome and the thalidomide–phocomelia tragedies, dramatically increased appreciation of the concept of drug treatment appropriate for age. The concept has also influenced practice with the increasing realization that the child is not a small adult, but rather a growing organism that undergoes continuous changes, at times rapidly, to achieve biological maturity. There was mounting evidence that, to ensure drug safety and efficacy at all periods of human development, from conception to adolescence, increased research was needed to clarify interactions among medications administered, physiologic events, and disease states.

The proliferation of workshops and conferences dealing with some aspect of children and drugs and the allocation of special sections to the subject within the general, pediatric, and pharmacologic publications attest to the concern of pediatricians and pharmacologists within the field of pediatric pharmacology. Interest seems to have reached a peak during the International Year of the Child, 1979, designated by the United Nations to encourage all countries and individuals to rekindle their commitments to children. Two specialized journals were planned during that year, and work started on *Pediatric Pharmacology*, the first textbook devoted exclusively to this issue. This multi-authored book presents chapters covering a broad panorama, from fundamental pharmacologic principles as they apply to developing organisms, to specific clinical advances. The writers, all recognized authorities in their fields, share a common interest in the well-being of children. The editor has achieved a comprehensive overview of the field by including chapters on ethical issues of drug study involving children, the behavioral aspects of compliance, and drug surveillance in this population.

This text will serve as a useful guide to all professionals responsible for the care of children as well as to those treating diseases in pregnant women. The compilation, in a single volume, of existing knowledge in the field of pediatric pharmacology serves one further purpose: because the book permits an evaluation of progress to date and indicates gaps

#### xvi / FOREWORD TO THE SECOND EDITION

in knowledge, pediatricians, pharmacologists, and obstetricians may be stimulated through this book to study some new element in pediatric or developmental pharmacology for the benefit of a most important patient—the child.

HENRY L. BARNETT, M.D.

Professor of Pediatrics Albert Einstein College of Medicine New York, New York

### **PREFACE**

Pediatric pharmacology and drug therapy may be viewed as manipulative physiology and biochemistry for the fetus, newborn infant, and growing child. This concept is based on the fact that drugs are used to restore and correct physiological and biochemical abnormalities which occur during pre- and postnatal development.

As advances in the knowledge of diseases and their diagnoses are made, the complexities of treatment, particularly by drugs, increase in tandem. Although therapeutic drug exposure in children has remained relatively constant, the number of drugs available to physicians and health care givers continues to increase. There is an increasing variety of antimicrobials, cardiovascular drugs, diuretics, immunosuppressants, antivirals, and other drugs for the management of sick pediatric patients. Safe and effective use of these agents in infants and children requires adequate knowledge of their pharmacologic properties, including drug action, metabolism, and disposition.

The second edition of *Pediatric Pharmacology: Therapeutic Principles in Practice* has been revised significantly to meet the needs of practitioners in the 1990s. The book has expanded from 24 chapters in the first edition to 52 chapters in this edition, plus an appendix on SI Units and a Drug Formulary appendix. The book is designed to provide relevant information on drugs and their uses in newborn infants, older infants, children, and adolescents. It was proposed as a quick reference for busy clinicians, house staff, students, nurses, pharmacists, and health care providers. It was also written as a general and basic reference for teaching pediatric pharmacology. It is hoped that researchers also will find it useful to understand the unique characteristics and dynamic changes in drug requirements and action during a period of intense growth and development.

The mechanisms of drug actions, the evidence of drug efficacy in certain disease states, dose, therapeutic guidelines, and drug toxicities are emphasized. The book was organized to parallel the distinct periods of early human development. Special sections useful in drug therapy such as therapeutic drug monitoring, adverse drug reactions, and epidemiologic considerations are also included. Certain aspects of pediatric drug therapy, particularly those relating to immunoactive drugs and vitamins, are not included owing to lack of information in these areas. We hope to correct these omissions in the next edition as the knowledge base for these agents in pediatrics increases.

Drugs are double-edged swords; although they can cure illnesses and restore health, they can also produce unwanted and, at times, unanticipated toxicities. The rational, intelligent, and safe use of drugs springs mainly from understanding their actions, uses, problems, and limitations. This understanding in turn will permit selection of the appropriate

#### xviii / PREFACE

drug and prescription of the optimal dosage. It is our utmost desire that this textbook can help those providers of care to children to maximize the benefits of pharmacologic agents while averting their adverse effects. Thus, this book will help in the promotion of health and well-being in children.

SUMNER J. YAFFE JACOB V. ARANDA